October 24, 2018 Esmo 2018 – Adaptimmune gets the wooden spoon The company emerges as the worst-performing stock after Europe’s most important cancer conference, which claims numerous other victims.
August 14, 2018 Most valuable unpartnered assets reveal a changing of the guard Annual analysis shows a new crop of biotech assets with ballooning valuations and no major partners.
August 22, 2017 The sector’s most valuable unpartnered assets – up for grabs or on the shelf? Pharma companies have passed on in-licensing drugs such as Kite Pharma’s CAR-T therapy and Incyte’s IDO inhibitor. Do they know something?
August 16, 2017 Biogen’s Alzheimer’s hope tops the sector’s most valuable pipeline projects The lack of clinical progress in Alzheimer's has not put analysts off valuing aducanumab at $10bn.